Showing 828 results
-
Media Release /Every 30 seconds, someone in the US is hospitalized for heart failure1; mobile solutions could play a role to help manage this disease Novartis Mobile Health Challenge attracted…
-
Media Release /Study result signals potential kidney benefit with RLX030;1 future studies will further explore this impact Kidney dysfunction affects approximately 30 percent of US heart failure…
-
Media Release /- Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer's; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6…
-
Media Release /- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years- Xolair® is approved for CIU patients age…
-
Media Release /Patient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) Patient adherence activities provide important education and support to help patients…
-
Media Release /-- Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia(1,2,3,4)-- Presentations include findings that 19 of…
-
Media Release /Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality(1,2)Phase III data show patients on…
-
Media Release /- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2)- Patients reported high satisfaction with self-administration of secukinumab pre-filled syringe or…
-
Media Release /Pivotal data in ALK+ NSCLC for Zykadia™; recently approved by US FDA, marking fastest oncology approval under Breakthrough Therapy designationFirst presentation of pivotal data from Phase III trial…
-
Media Release /- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)- The filing was submitted by the University…
